RHEO Meditech

2F., 44 Muhak-ro-45-gil, Dongdaemun-gu, Seoul, 02578, Republic of Korea
**TEL** +82-2-537-5111 **FAX** +82-2-537-5103
**E-mail** info@any-sis.com
**Website** www.any-sis.com




# ANYSIS

Platelet Function Tests

## Platelet Function Test

**Assessment of inherited, acquired, or drug induced platelet dysfunction.**
**ADP, EPI, Aspirin, P2Y12 inhibitor**

| | |
|---|---|
| **Innovation** | In Healthcare |
| **Diagnostic** | Screening device |
| **POCT** | Point of Care Technology |
| **ANYSIS** | Platelet dysfunction tests |

/ 01

# ANYSIS™ SYSTEM

## Anysis™ System

### Platelet Function Test

The Anysis™ system test provides assessment for inherited, acquired, or drug-induced platelet dysfunction in various clinical environments.

Through in vivo vascular mimicking microfluidics, the system measures a realistic primary hemostasis associated with platelet aggregation.

Individual tests only require 200μL of citrated whole blood sample and are completed within 4 minutes of initiation.

### Key Features of Anysis™

**01**

Screens platelet function for impaired primary hemostasis, such as von Willebrand Disease.

**02**

Provides high sensitivity for congenital platelet dysfunction, such as Glanzmann thrombasthenia

**03**

Evaluates platelet dysfunction in multiple clinical settings, such as presurgical screening.

**04**

Assesses platelet dysfunction caused by aspirin.

**05**

Detects platelet dysfunction caused by P2Y12-receptor inhibitors.

**06**

Aids in monitoring the progress of antiplatelet therapy by measuring the patient's antiplatelet response caused by aspirin and P2Y12-receptor inhibitors.





## Precision tests for

- **Bleeding risk screening**
- **Antiplatelet response monitoring**




## Bleeding Risk Screening

Anysis Epinephrine Anysis ADP

| - | Collagen-EPI Test | Collagen-ADP Test |
|---|---|---|
| **Clinical uses** | • Routine screening<br>• Aspirin response test<br>• vWD detection<br>• Thrombocytopathies detection | • vWD detection<br>• Thrombocytopathies detection<br>• Abciximab, Eptifibatide, Tirofiban |
| **Sample** | • Whole blood in 2mL vacuum tubes with 3.2% sodium citrate | • Whole blood in 2mL vacuum tubes with 3.2% sodium citrate |

## Antiplatelet Response Monitoring

Anysis Aspirin Anysis P2Y12

| - | Aspirin Test | P2Y12 Test |
|---|---|---|
| **Clinical uses** | • Patient response to Aspirin | • Patient response to P2Y12-inhibitor |
| **Sample** | • Whole blood in 2mL vacuum tubes with 3.2% sodium citrate | • Whole blood in 2mL vacuum tubes with 3.2%sodium citrate |

/ 02

# HIGHLIGHTS

## Fully Automated and User Friendly System

With a single pipetting, the whole test is automatically operated.

Load 200uL of citrated whole blood sample.

Push the test cartridge, and initiate testing.



Anysis™ system automatically engages in and completes the test within 4 minutes.

Once completed, test cartridge is ejected out and the test result is printed.

## Bubble-Free Test

Air bubbles in blood sample are naturally excluded in the test



## Operator-Independent Results

Measurements are not affected by operator's skillfulness.



## Stenosed Thrombosis Model

Flow through microbeads mimics stenosed vascular thrombosis.

## Hematocrits-Independent

Hematocrit variations do not affect the result of Anysis.




## Fibrinogen-Independent

Blood fibrinogen concentrations do not affect the result of Anysis.




## Platelet-Adhesion Characteristic

Adhesion characteristic is fully emphasized in microscale pores




## Visible Results

Printed test result can visibly be confirmed by observing the ejected test cartridge.



/ 03

# OPERATING PRINCIPLES

**01. Activation** **02. Adhesion** **03. Aggregation** **04. Occlusion**














## Upstream Activation & Downstream Adhesion

Upstream Activation and Downstream Adhesion technology was developed with a focus on simulating the in vivo environment of injured blood vessels.

**Upstream**
Specific agonist(s) is either mixed with blood in a microchamber or activated by shear force by a stirrer.

**Downstream**
Adhesion is induced as activated platelets pass through the packedmicrobeads coated with the same ECM material as the ECM material commonly found in wounded blood vessels (e.g.collagen or fibrinogen).




## Aggregation, Occlusion & Detection

**Aggregation**
Adhesion of activated platelets and ECM material naturally recruits additional activated platelets to aggregate to one another.

**Occlusion & Detection**
Accumulated platelet aggregation in the microbeads section ultimately leads to occlusion of the blood flow. When the test has completed, the instrument measures and reports the final MD in a millimeter unit, which does not require any calculations or conversions.

/ 04

# MIGRATION DISTANCE




## Elongated MD

Indicates that the platelets are not normally functioning. This implies impaired primary hemostasis, congenital platelet dysfunction, and/or effective anti-platelet therapy.

## Shortened MD

Indicates that the platelets are normally functioning. This reflects normal platelet function and/or ineffective anti-platelet therapy.








/ 05

# TECHNICAL SPECIFICATIONS

## INSTRUMENT

| | | | | |
|---|---|---|---|---|
| **Model** | Anysis-300S | | | |
| **Image** |  | | | |
| **Test Types** | Epinephrine | ADP | Aspirin | P2Y12 |
| **Sample Volume** | 200 µL citrated whole blood | | | |
| **Test Time** | Less than 4 minutes | | | |
| **Measuring Index** | MD (Migration Distance, mm) | | | |
| **Cartridge** | A-1002 | A-1003 | A-1004 | A-1005 |
| **Cut-off Values** | 210 | 190 | 205 | 225 |
| **Operation Mechanisms** | Pressure-drivien Microfluidics | | | |

## CONSUMABLES

| Test Cartridge | |
|---|---|
| **C/EPI & C/ADP** | **Aspirin & P2Y12** |



# RHEOMEDITECH

RheoMeditech Inc. is a leading manufacturer of wide range of in vitro diagnostic analyzers, test kits, and consumables. Our line of instruments and test kits are specially designed to elevate the best performance to hospitals and laboratories. RheoMeditech offers early screening and diagnostics that provide health care professionals to make better decisions. With greater trust, we can help people achieve better health through our early diagnosis systems with innovative technology. The best treatment starts with early detection.

## Certificate









## We provide what patients need now.

### References

Piao, Jinxiang, et al., "Performance comparison of the PFA-200 and Anysis-200: Assessment of bleeding risk screening in cardiology patients" *Clinical Hemorheology and Microcirculation* (2021) DOI 10.3233/CH-211185

Piao Jinxiang et al., "Performance comparison of aspirin assay between anysis and verifynow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases" *Clinical Hemorheology and Microcirculation* (2021) DOI 10.3233/CH-211171

Piao, Jinxiang et al., "Assessment of therapeutic platelet inhibition in cardiac patients: Comparative study between VerifyNow-P2Y12 and Anysis-P2Y12 assay" *Clinical Hemorheology and Microcirculation* 78 (2021) 439–448. DOI 10.3233/CH-211104